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Nodal expression (χ2 = 30.452, P < 0.001). Cox multivari-
ate regression showed that high Nodal expression was an 
independent risk factor affecting the prognosis of GAC 
patients (P = 0.000, RR = 2.976). Furthermore, patients 
with tumors in which both Nodal and YAP1 were expressed 
at high levels had the worst prognosis.
Conclusions Elevated Nodal expression is a marker of 
poor prognosis in gastric cancer. Patient outcome is fur-
ther worsened if Nodal and YAP1 are both expressed in 
the same tumor. The datas we present here suggest that the 
inhibition of Nodal signaling may represent a new thera-
peutic strategy for the treatment of gastric adenocarcinoma.
Keywords Nodal · YAP1 · Gastric adenocarcinoma · 
Prognosis
Introduction
Nodal, a member of the transforming growth factor-β 
(TGF-β) superfamily, regulates many diverse cellular 
processes, including the growth and differentiation of 
embryonic stem cells and the plasticity and invasiveness 
of malignant tumor cells. As such, Nodal helps regulate 
the pluripotency of embryonic stem cells and cancer cells 
(James et al. 2005). Nodal signaling also plays a critical 
role during the development of vertebrates, echinoderms, 
and protostomes. During early vertebrate development, 
Nodal is necessary and sufficient for endomesoderm induc-
tion and patterning of anteroposterior (AP), dorsoventral 
(DV), and left–right (LR) axes. During echinoderm devel-
opment, Nodal is important for determining DV and LR 
asymmetry. In contrast, in protostomes, Nodal signaling 
is only involved in establishing LR asymmetry (Röttinger 
et al. 2015). While Nodal is an essential molecule early in 
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Purpose To investigate the correlation between Nodal and 
YAP1 expression and the clinicopathological characteris-
tics of gastric adenocarcinoma (GAC).
Methods Quantitative real-time RT-PCR, Western blot, and 
immunohistochemistry were performed to measure Nodal 
and YAP1 mRNA and protein in 20 fresh frozen samples 
and 220 paraffin-embedded GAC tissues with their paired 
non-tumor mucosa (PNTM). The prognostic values of 
Nodal and YAP1 were evaluated in 161 GAC patients using 
univariate and multivariate analyses.
Results Both mRNA and protein expression of Nodal and 
YAP1 were significantly increased in GAC compared to 
PNTM (P < 0.05). Immunohistochemistry showed that 
Nodal was more highly expressed in 56.4 % GAC samples 
compared to PNTM; additionally, Nodal expression cor-
related with depth of tumor invasion, lymph node metas-
tasis, and distant metastasis (all P < 0.05). There was no 
association between Nodal and YAP1 in GAC (P = 0.171). 
Kaplan–Meier analysis showed that the outcome of Nodal-
high patients was significantly worse than those with low 
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development, it is thought to be largely absent from adult 
tissues; the few exceptions include some adult stem cell 
populations and some highly dynamic reproductive tis-
sues (Aykul et al. 2015). Nodal signaling is regulated, at 
least in part, by secreted proteins Lefty and Cerberus. Dur-
ing development, Nodal exerts its functions both by regu-
lating its own expression and via unilateral activation of 
downstream genes, such as Lefty and Pitx. In turn, Lefty 
and Pitx regulate expression of several additional genes, 
many of which have roles in proliferation and differentia-
tion (Soukup et al. 2015). For example, one study showed 
that exposure of tumor cells to an hESC microenvironment 
containing Lefty resulted in decreased Nodal expression, 
colony forming ability, and tumorigenicity (Postovit et al. 
2008). Additionally, Cerberus, another Nodal inhibitor that 
functions by preventing the interaction between Nodal and 
its receptor, profoundly suppresses migration, invasion, 
and colony formation ability of breast cancer cells (Aykul 
et al. 2015). Studies such as these suggest that approaches 
to decrease Nodal expression may have some therapeu-
tic value. This is particularly relevant since several ear-
lier studies have established that Nodal is up-regulated in 
various cancers, including breast cancer (Kirsammer et al. 
2004), melanoma (Strizzi et al. 2015), endometrial can-
cer (Cruz et al. 2015), and pancreatic cancer (Kong et al. 
2015). Nodal appears to play many roles during onco-
genesis as well; indeed, Nodal has been associated with 
increased tumor angiogenesis, invasion, and metastasis.
YAP1 is a transcriptional coactivator of the Hippo path-
way with roles in tumorigenesis. Since it regulates tumor 
cell proliferation and apoptosis, YAP1 has been described 
as a candidate oncogene (Sudol 1994). Several studies have 
reported increased expression of Nodal and YAP1 in many 
tumor types, including melanoma, liver cancer, breast can-
cer, ovarian cancer, and glioma. This increased expression 
in cancer suggests that Nodal and YAP1 might play impor-
tant roles in tumor proliferation, angiogenesis, invasion, 
and metastasis.
Importantly, previous studies have reported cross talk 
between components of the Hippo and TGF-β pathways, 
both at the level of intracellular signaling and transcrip-
tional regulation (Grannas et al. 2015). As one example in 
endothelial cells, TGF-β induces nuclear localization of a 
Smad2/3/4 complex, which activates expression of Snail, 
Twist1, and Slug, key transcription factors required for 
epithelial–mesenchymal transition (EMT). YAP1 interacts 
with this complex, and loss of YAP1 disrupts the TGF-β-
mediated up-regulation of Snail, Twist1, and Slug (Zhang 
et al. 2014). These findings highlight the potential impor-
tance of cross talk between these two pathways for cel-
lular processes. Despite this, to date, potential roles for 
Nodal and YAP1 have not been reported in gastric adeno-
carcinoma (GAC). In this study, we measured mRNA and 
protein expression of both Nodal and YAP1 in GAC and 
paired non-tumor mucosa (PNTM). We examined pos-
sible correlation between expression of these factors and 
several clinicopathological variables. The data we present 
here suggest that inhibition of Nodal signaling may repre-
sent a new therapeutic strategy for the treatment of gastric 
adenocarcinoma.
Materials and methods
Samples and clinicopathological data
Two hundred and twenty surgically resected gastric adeno-
carcinoma (GAC) specimens and paired non-tumor mucosa 
(PNTM) (obtained at a location greater than 5 cm away 
from the edge of the primary tumor) were collected at 
the First Affiliated Hospital of China Medical University. 
Specimens were fixed in 10 % neutral formalin. Conven-
tional wax baits were cut consecutively into 4 μm sections 
and then subject to conventional H&E staining to deter-
mine pathological diagnosis. Twenty additional fresh fro-
zen specimens from postoperative GAC and corresponding 
PNTM were collected and preserved at −80 °C for qRT-
PCR and Western blot. None of the patients had received 
radiotherapy or chemotherapy prior to surgery. None of the 
patients received adjuvant or palliative therapy either. Clin-
ical and pathological data for all patient samples used in the 
study are listed in Table 2. Informed consent was obtained 
from the Ethics Committee in the First Affiliated Hospital 
of China Medical University.
RNA extraction and quantitative real‑time reverse 
transcriptase PCR (qRT‑PCR)
Total RNA was isolated from 20 tumor/non-tumor paired tis-
sue samples using the EASYspin Plus kit (Aidlab Biotechnol-
ogies, Beijing) according to the manufacturer’s instructions. 
RNA quantity and quality were analyzed with Nanodrop 
1000 (Thermo Fisher Scientific). Isolated RNA was reverse-
transcribed to cDNA using the PrimeScript® RT reagent kit 
(TaKaRa, Dalian, China) according to the manufacturer’s pro-
tocol. Primers to measure the expression of genes of interest 
were designed using Prime5 software. Primer sequences are as 
follows: Nodal—Sense 5′-ACATCATCCGCAGCCTACA-3′, 
anti-sense 5′-AGCCCATGCCAGATCCTC-3′, YAP1— 
Sense 5′-TACGATACAAGGCTGTTAGAGAG-3′, anti-
sense 5′-TTGAGATGCATGCTTTGCATAC-3′; GAPDH—
sense 5′-GAAGGTGAAGGTCGGAGTC-3′, and anti-sense 
5′-GAAGATGGTGATGGGATTTC-3′.
Each PCR was prepared in a total volume of 10 µl, 
which included each primer, diluted cDNA templates, 
and SYBR® Premix TaqTM II (TaKaRa, Dalian, China). 
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Cycling conditions for qRT-PCR were as follows: 95 °C for 
30 s followed by 40 cycles of 95 °C for 5 s and annealing at 
58.5 °C for 30 s. Melting curves were generated by 95 °C 
for 15 s, 60 °C for 30 s, and 95 °C for 15 s. Data were 
calculated using the 2-ΔΔCt method. The mRNA level of 
each sample was normalized to that of GAPDH mRNA, 
and each cDNA sample was run in triplicate.
Protein extraction and Western blot
Protein was harvested from samples using lysis buffer con-
taining phenylmethylsulfonylfluoride (PMSF) at 4 °C. Total 
extracted proteins were quantified using a BCA protein assay 
kit (ComWin Biotech, Beijing, China). Samples were boiled 
at 95 °C for 5 min, and then, 50 μg of protein was electro-
phoretically separated using 10 % SDS-PAGE gels (Invitro-
gen). Following electrophoresis, samples were transferred to a 
polyvinylidene difluoride (PVDF) membrane via wet transfer. 
PVDF membranes were blocked with 5 % nonfat dry milk in 
Tris–phosphate buffer containing 0.05 % Tween 20 (TBS-T) 
for 1 h at room temperature, and then incubated with primary 
antibodies at room temperature overnight. The following pri-
mary antibodies were used in this study: rabbit anti-Nodal 
polyclonal antibody (working dilution 1:1000, MILLIPORE), 
rabbit anti-YAP1 monoclonal antibody (1:1000, Abcam, 
Britain), and β-actin (1:1000, ZhongShan-Golden Bridge, 
Beijing), which was used as an internal loading control. 
Membranes were then incubated with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibodies 
(1:1000, ZhongShan-Golden Bridge, Beijing) and visualized 
using an enhanced chemiluminescence (ECL) detection sys-
tem. Blots were visualized using an ECL Kit (ComWin Bio-
tech, Beijing, China) and quantified using ImageJ software. 
Results are expressed as fold change compared to the control 
values. All experiments were performed at least three times.
Tissue microarray and immunohistochemistry
Two hundred and twenty GAC and paired normal mucosa 
samples were fixed in 10 % formalin, embedded in paraffin, 
and cut into 4 μm-thick sections. All samples were evalu-
ated by two experienced pathologists, who confirmed the 
diagnoses and marked various target lesions. Six blocks of 
tissue microarray containing 220 gastric adenocarcinomas 
and their corresponding normal gastric mucosa were con-
structed using microarrayer (USA). The six blocks of tissue 
microarray were then cut to yield 4-μm serial sections and 
placed on glass slides using an adhesive-tape transfer sys-
tem for immunohistochemistry.
Nodal and YAP1 protein expression were measured 
using two-step immunohistochemistry. Rabbit anti-Nodal 
polyclonal antibody (working dilution 1:50) and rabbit 
anti-YAP1 monoclonal antibody (working dilution 1:50) 
were purchased from MILLIPORE and Abcam, respec-
tively. The DAB kit was purchased from Fuzhou Maixin 
Company (Fuzhou, China). The PV-9000 kit was obtained 
from Beijing Zhongshan Goldenbridge Biotechnology 
Company (Beijing, China). Tissue microarray slides were 
deparaffinized in xylene and hydrated with alcohol before 
being placed in 3 % H2O2 methanol blocking solution. This 
was then followed by heat-induced antigen retrieval. The 
slides were incubated with primary antibodies overnight at 
4 °C, stained with the PV-9000 detection system, and coun-
terstained with hematoxylin. All procedures were carried 
out according to the manufacturer’s instructions. For nega-
tive controls, sections were treated with 0.01 M phosphate-
buffered saline instead of primary antibodies.
Assessment of immunohistochemistry staining
Nodal or YAP1 positivity was defined as samples displaying 
clear brown granules either in the cytoplasm or nucleus. The 
expression of Nodal and YAP1 was determined by assign-
ing proportion and intensity scores to both tumor cells and 
adjacent gastric mucosa epithelial cells. This type of stain-
ing analysis has been previously described (Vandeputte et al. 
2002). The proportion score was assigned based on the pro-
portion of positive cells (0, none; 1, ≤10 %; 2, 11–25 %; 3, 
26–50 %; 4, >50 %). The intensity score was assigned based 
on comparison to YAP1-positive or Nodal-positive internal 
controls (0, none; 1, weak; 2, intermediate; 3, strong). The 
total score for Nodal or YAP1 expression, ranging from 0 to 
12, was the product of the proportion and intensity scores. 
The expression was categorized as negative (0), (−); low 
(score 1–3), (1+); intermediate (score 4–6), (2+); or high 
(score 7–12), (3+). According to the above-mentioned cri-
teria, samples scoring 0–1+ were considered the low-expres-
sion group, and samples scoring 2+ to 3+ were considered 
the high-expression group for subsequent statistical analysis.
Statistical analysis
Categorical data have been described using frequencies 
and percentages. Continuous data have been presented as 
means with standard deviations for normally distributed 
data. Statistical analysis was performed using SPSS 17.0 
software. Either Chi-square test or Fisher’s exact test was 
used to differentiate the rates of different groups. Time-to-
event data were estimated by the Kaplan–Meier method 
and analyzed with the log-rank test. The cumulative overall 
survival rates were calculated using life table techniques, 
illustrated by Kaplan–Meier plots. The multivariable analy-
sis model was fit using a Cox proportional hazards regres-
sion model using SPSS 17.0. The enter method was used to 
determine a final Cox model. All statistical analyses were 
two-sided, and significance was assigned at α = 0.05.
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Results
Nodal and YAP1 mRNA expression are significantly 
up‑regulated in GAC
To determine expression levels of Nodal and YAP1, we per-
formed qRT-PCR using RNA isolated from GAC samples 
and from adjacent normal gastric mucosa. Nodal mRNA 
was significantly higher in GAC tissue compared to paired 
normal mucosa (P = 0.046). Similarly, YAP1 mRNA 
expression was also elevated in GAC specimens compared 
to paired normal mucosa (P = 0.013) (Fig. 1; Table 1).
Nodal and YAP1 protein expression are significantly 
up‑regulated in GAC
We next performed Western blot from GAC samples and 
their matched normal tissue to determine protein expres-
sion of Nodal and YAP1. Consistent with our mRNA analy-
sis, we found significantly increased protein expression of 
both Nodal (P = 0.017) and YAP1 (P = 0.038) in GAC tis-
sues compared to matched normal mucosa (Fig. 1; Table 1).
Expression of Nodal and YAP1 are not correlated 
in GAC
Since both Nodal and YAP1 are elevated in GAC samples 
compared to normal mucosa, we next determined if there 
was any correlation between expressions of these two fac-
tors. We found no correlation between Nodal and YAP1 at 
either the mRNA (P = 0.78) or protein (P = 0.336) level in 
either GAC or paired normal tissue expression (Fig. 1).
High Nodal protein expression is associated with poor 
clinicopathological variables in GAC
We next wanted to determine if there was any correlation 
between Nodal expression and clinicopathological variables 
in GAC. Immunohistochemistry showed that Nodal protein 
was expressed both in the cytoplasm and nucleus of GAC 
samples. A total of 56.4 % (124/220) of GAC samples stained 
positive for Nodal, in contrast to the only 4.3 % (8/186) of 
paired normal tissue showing a positive stain (P < 0.01). Fur-
thermore, Nodal expression in GAC correlated with depth of 
tumor invasion, lymph node metastasis, distant metastasis, 
and TNM staging (all P < 0.005) (Fig. 2; Table 2).
Fig. 1  Expression of Nodal and YAP1 mRNA and protein in GAC. 
Nodal mRNA (a) and YAP1 mRNA (b) were significantly up-regu-
lated in GAC compared with PNTM (P < 0.05); similar results were 
found when examining protein expression (c–e). However, there 
was no correlation between Nodal and YAP1 expression at either the 
mRNA (f) or protein (g) level
Table 1  Nodal and YAP1 mRNA and protein expression in GC and 
paired normal mucosa
Bold values indicates that statistical significance of P value is less 
than 0.05
Groups n Nodal expression P YAP1 expression P
mRNA 0.046 0.013
 GC 20 0.126 ± 0.177 0.105 ± 0.069
 Normal 20 0.056 ± 0.063 0.075 ± 0.052
Protein 0.017 0.038
 GC 32 1.0699 ± 0.9241 0.8494 ± 0.2893
 Normal 32 0.6929 ± 0.2965 0.7012 ± 0.3667
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High Nodal expression is associated with poor 
prognosis in GAC
In this study, a total of 161 cases were followed up for 
52 months after surgery. The median survival time was 
34 ± 4.79 months. A total of 88 deaths occurred during 
follow-up, and all causes of death were cancer-related. 
Kaplan–Meier survival curves were plotted, and a log-
rank test was used to evaluate the effect of high Nodal 
expression on patient outcome. The mean survival time of 
patients in the Nodal-high group was 23.58 ± 1.98 months, 
significantly shorter than in the Nodal-low group 
(40.90 ± 1.88 months) (P < 0.001). These results indicate 
that high Nodal expression is associated with poor progno-
sis in gastric adenocarcinoma (Fig. 2m; Table 3).
Patients with GAC tumors expressing both Nodal 
and YAP1 exhibit the worst overall prognosis
To evaluate potential interaction between Nodal and YAP1 on 
GAC prognosis, patients were divided into four groups accord-
ing to their Nodal and YAP1 expression status. The groups 
consisted of patients with tumors that were Nodal−YAP1−, 
Nodal−YAP1+, Nodal+YAP1−, and Nodal+YAP1+. 
Fig. 2  Correlation between expression of Nodal and YAP1 protein 
and prognosis of patients with GAC. Compared with the PNTM (a), 
Nodal expression was significantly up-regulated in GAC (b–f). Nodal 
expression (e–h) was not correlated with YAP1 expression (i–l) in the 
same case of GAC (e vs. i, f vs. j, g vs. k, h vs. l). Two-step IHC 
×400. Kaplan–Meier analyses of the effects of Nodal and YAP1 
expressions on patient survival in GAC showed that overall survival 
for patients with high Nodal expression was significantly worse than 
that with low expression (P = 0.000, m). Overall survival for patients 
with YAP1 high-expression was significantly worse than that in the 
YAP1 low-expression group (P = 0.001, n). Furthermore, there was 
an interaction between Nodal and YAP1 expression on GAC outcome, 
as patients with tumors with high expression of both Nodal and YAP1 
had the worst overall prognosis (o)
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Kaplan–Meier analysis showed that overall survival for 
patients with YAP1 high-expression was significantly worse 
than in patients with low YAP1 expression (P = 0.001, 
Fig. 2n). Patients with low expression of both Nodal and YAP1 
(Nodal−YAP1−) demonstrated the best outcome. In contrast, 
patients with high expression of both proteins (Nodal+YAP1+) 
demonstrated the worst outcome (Fig. 2o; Table 3.)
Discussion
Nodal is a member of the TGF-β superfamily that regu-
lates many important aspects of early development, includ-
ing germ layer specification and axis patterning. While its 
expression in many adult tissues is down-regulated, it has 
been shown to be re-expressed in cancer cells, where it 
Table 2  Correlation between 
Nodal and YAP1 expression 
and clinicopathological features 
in GC
HPR high positive rate, Histol. histological, Papi. papillary, ade. adenocarcinoma, diff. differentiation, 
Undiff. undifferentiated, Car carcinoma, SRC signet ring cell cancer, Ln. lymph node
Bold values indicates that statistical significance of P value is less than 0.05
Variable n Nodal expression HPR (%) χ2 P value
Low High
Age (year) 3.696 0.055
 ≤55 82 43 39 47.6
 >55 138 54 84 60.9
Gender 0.018 0.892
 Female 67 30 37 55.2
 Male 153 67 85 56.2
Borrmann’s types 0.26 0.61
 I + II 30 12 18 60.0
 III + IV 189 85 104 55.0
WHO’s histology types 8.930 0.159
 Papillary. Ade. 8 3 5 62.5
 Tubular Ade.
  Well Diff. 14 9 5 35.7
  Moderately Diff. 74 36 38 51.4
  Poorly Diff. 99 35 64 64.6
 Un-differentiated car. 3 1 2 66.7
 Signet ring cell Car. 7 5 2 28.6
 Mucinous Ade. 15 8 7 46.7
Lauren’s types 0.735 0.692
 Intestinal 80 38 42 53.5
 Diffuse 102 42 60 58.8
 Mixed 38 17 21 55.3
Depth of invasion 8.899 0.003
 T1 + T2 36 24 12 33.3
 T3 + T4 184 73 111 60.3
Ln metastasis 19.669 <0.001
 N0 60 41 19 31.7
 N1–3 160 56 104 65.0
Distant metastasis 23.815 <0.001
 M0 167 89 78 46.7
 M1 53 8 45 84.9
TNM staging 26.416 <0.001
 I + II 71 49 22 31
 III + IV 149 48 101 67.8
YAP1 expression 1.8712 0.171
 Low 41 22 19 46.3
 High 179 75 104 58.1
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likely promotes tumorigenesis. This claim is supported by 
data showing that down-regulation of Nodal significantly 
reduces tumorigenicity of several cancer cell line mod-
els (Lee et al. 2010; Quail et al. 2012; Topczewska et al. 
2006). YAP1 is a member of the Hippo signaling path-
way, which regulates organ size by coordinating cellular 
proliferation and apoptosis. Overexpression of YAP1 has 
been shown to correlate with disease progression and poor 
prognosis of gastric cancer. Previous studies have reported 
cross talk between components of the Hippo and TGF-β 
pathways, both at the level of intracellular signaling and 
transcriptional regulation (Grannas et al. 2015). Despite 
this, interplay between these two pathways in gastric ade-
nocarcinoma has not been thoroughly examined. To gain 
insight into the role of Nodal and YAP1 in gastric cancer, 
we examined their expression in a panel of patient tumor 
samples and matched normal tissue. We found that elevated 
expression of either Nodal or YAP1 is associated with 
Table 3  Univariate and 
multivariate analyses of 
different prognostic factors in 
161 patients with GC
Ade Adenocarcinoma, Diff. Differentiated, Car. Carcinoma, Ln. lymph node
a Log-rank test; b Cox regression model
Variable Univariate analysisa Multivariate analysisb
n Mean survival (months) P value HR (95 % CI) P value
Borrmann’s types 0.289 1.113 (0.646–1.985) 0.663
 I + II 22 29.55
 III + IV 139 32.62
WHO’s histology types 0.638 1.096 (0.913–1.317) 0.324
 Papillary. Ade. 6 32.50
 Tubular Ade.
  Well Diff. 11 33.80
  Moderately Diff. 56 35.29
  Poorly Diff. 70 29.71
 Un-differentiated car. 3 35.67
 Signet ring cell car. 5 16.60
 Mucinous Ade. 10 26.07
Lauren’s types 0.354 1.055 (0.747–1.492) 0.760
 Intestinal 56 35.11
 Diffuse 77 31.41
 Mixed 28 28.13
Depth of invasion 0.001 1.886 (0.895–3.975) 0.095
 T1 + T2 28 43.96
 T3 + T4 133 29.54
Ln metastasis 0.001 0.450 (0.208–0.974) 0.043
 N0 43 41.06
 N1–3 118 28.64
TNM staging <0.001 6.999 (2.754–17.786) <0.001
 I + II 52 46.15
 III + IV 109 25.23
Nodal protein expression <0.001 2.487 (1.546–4.001) <0.001
 Low 80 40.90
 High 81 23.58
YAP1 protein expression 0.001 2.506 (1.195–5.257) 0.015
 Low 29 44.90
 High 132 29.22
Nodal and YAP1 expression <0.001
 Nodal−YAP1− 18 50.30
 Nodal−YAP1+ 59 37.35
 Nodal+YAP1− 14 39.38
 Nodal+YAP1+ 70 21.51
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several clinicopathological variables. Additionally, patients 
with tumors expressing high levels of both Nodal and YAP1 
displayed the worse prognosis. The data we present here 
suggest that inhibition of the Hippo and TGF-β pathways in 
gastric adenocarcinoma may have some therapeutic benefit.
We first examined mRNA and protein expression of 
Nodal and YAP1 in a panel of gastric adenocarcinoma 
patient samples and matched normal tissue. We measured 
significant overexpression of Nodal and YAP1 at both the 
mRNA and protein levels in tumors compared to normal 
tissue. These findings suggest that these factors and their 
respective signaling pathways might be drivers of disease 
progression. This is supported by earlier work showing 
that YAP1 expression correlates with progression, metasta-
sis, and poor prognosis in patients with gastric carcinoma 
(Hu et al. 2014). Moreover, Nodal has been found to be 
up-regulated in various cancers, including breast cancer 
(Kirsammer et al. 2004), endometrial cancer (Cruz et al. 
2015), pancreatic cancer (Kong et al. 2015), and mela-
noma (Strizzi et al. 2015). The melanoma study is particu-
larly interesting since the authors showed no expression 
of Nodal in normal skin but increased nodal expression in 
approximately 60 % of invasive melanoma cases. These 
data correlate with the findings we present here and support 
the fact that Nodal expression is associated with advanced 
disease state and overall prognosis.
We expanded on these initial observations by examin-
ing the potential correlation between Nodal and YAP1 
expression and several clinicopathological variables. Nodal 
expression correlated with depth of tumor invasion, lymph 
node metastasis, and distant metastasis. Furthermore, we 
found that either high Nodal or YAP1 expression served 
as an independent risk factor for GAC prognosis. Previ-
ous work from our group has already established that 
YAP1 also correlates with these same clinicopathological 
variables (Hu et al. 2014). Importantly, we discovered that 
patients with tumors in which both Nodal and YAP1 were 
expressed at high levels had the worse overall prognosis. 
These data suggest that these two factors or their respec-
tive signaling pathways may cooperate to promote disease 
progression. Since we did not detect significant correla-
tion between expression of Nodal and YAP1 themselves, 
it is possible that the Hippo and TGF-β pathways interact 
downstream at the signal transduction level to enhance dis-
ease pathogenesis. Additional work is required to better 
understand the nature of the cross talk between these two 
pathways.
The work we present here is not without its limitations. 
Most notably, the data we present here do not address the 
reason why gastric adenocarcinomas expressing both Nodal 
and YAP1 at high levels have the worse overall prognosis. 
Second, sample size is limited, which prevents us from draw-
ing vast conclusions; additional studies with more samples 
would enhance the work we present here. Third, follow-up 
information for all patients after surgery was not available; 
this may have introduced bias into our analysis. Finally, the 
data we present are largely correlative. Follow-up studies in 
either cell lines or animal models in which levels of Nodal or 
YAP1 could be manipulated would help establish a possible 
causal role for either of these factors in disease progression.
In summary, we show that Nodal and YAP1 are 
increased in gastric adenocarcinomas compared to normal 
tissue. Elevated Nodal expression is a marker of poor prog-
nosis in gastric cancer. Patient outcome is further worsened 
if Nodal and YAP1 are both expressed in the same tumor. 
The data we present here suggest that inhibition of Nodal 
signaling may represent a new therapeutic strategy for the 
treatment of gastric adenocarcinoma.
Acknowledgments This work was supported by the National Natu-
ral Science Foundation of China (Nos. 81071650; 30973503), Special 
foundation for Science and Technology Program in Liaoning Prov-
ince, China (2013225303-103; 2011404013-3), and the Supporting 
Project for Climbing Scholars in Liaoning Provincial Universities, 
China (2009–2012).
Authors’ contributions Yan Xin conceived and supervised this 
study and revised the manuscript. Ping Li and Dan Sun made equal 
contributions to this article, including performing experiments, inter-
preting data, and drafting the manuscript. Xiaoting Li and Yingjian 
were responsible for the statistical analyses. Wenhui Li, Jing Zhao, 
Ying Wang, and Huan Wang were responsible for collecting tissue 
specimens and relevant clinicopathological data. All authors read and 
approved the final manuscript.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval This article does not contain any studies with 
human participants or animals performed by any of the authors.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
Aykul S, Ni W, Mutatu W, Martinez-Hackert E (2015) Human Cer-
berus prevents nodal-receptor binding, inhibits nodal signal-
ing, and suppresses nodal-mediated phenotypes. PLoSOne 
10:e0114954. doi:10.1371/journal.pone.0114954
Cruz CD, Del Puerto HL, Rocha AL, Cavallo IK, Clarizia AD, Petra-
glia F, Reis FM (2015) Expression of Nodal, Cripto, SMAD3, 
phosphorylated SMAD3, and SMAD4 in the proliferative 
1773J Cancer Res Clin Oncol (2016) 142:1765–1773 
1 3
endometrium of women with endometriosis. Reprod Sci 22:527–
533. doi:10.1177/1933719114549855
Hu X, Xin Y, Xiao Y, Zhao J (2014) Overexpression of YAP1 is corre-
lated with progression, metastasis and poor prognosis in patients 
with gastric carcinoma. Pathol Oncol Res 20(4):805–811
James D, Levine AJ, Besser D, Hemmati-Brivanlou A (2005) TGF-
beta/activin/nodal signaling is necessary for the maintenance 
of pluripotency in human embryonic stem cells. Development 
132:1273–1282. doi:10.1007/s00421-008-0955-8
Kirsammer G, Strizzi L, Margaryan NV, Gilgur A, Hyser M, 
Atkinson J, Kirschmann DA, Seftor EA, Hendrix MJ (2004) 
Nodal signaling promotes a tumorigenic phenotype in human 
breast cancer. Semin Cancer Biol 29:40–50. doi:10.1016/j.
semcancer.2014.07.007
Kong B, Wang W, Esposito I, Friess H, Michalski CW, Kleeff J 
(2015) Increased expression of Nodal correlates with reduced 
patient survival in pancreatic cancer. Pancreatology 15:156–161. 
doi:10.1016/j.pan.2015.02.001
Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, 
Liu LW, Wei HW, Lee HM (2010) Nodal promotes growth 
and invasion in human gliomas. Oncogene 29(21):3110–3123. 
doi:10.1038/onc.2010.55
Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky 
A, Wheaton WW, Abbott DE, Seftor RE, Hendrix MJ (2008) 
Human embryonic stem cell microenvironment suppresses the 
tumorigenic phenotype of aggressive cancer cells. Proc Natl 
Acad Sci USA 105:4329–4334. doi:10.1073/pnas.0800467105
Quail DF, Zhang G, Walsh LA, Siegers GM, Dieters-Castator DZ, 
Findlay SD, Broughton H, Putman DM, Hess DA, Postovit LM 
(2012) Embryonic morphogen nodal promotes breast cancer 
growth and progression. PLoS ONE 7(11):e48237. doi:10.1371/
journal.pone.0048237
Röttinger E, DuBuc TQ, Amiel AR, Martindale MQ (2015) 
Nodal signaling is required for mesodermal and ventral but 
not for dorsal fates in the indirect developing hemichordate, 
Ptychodera flava. Biol Open 4:830–842. doi:10.1242/bio.011809
Soukup V, Yong LW, Lu TM, Huang SW, Kozmik Z, Yu JK 
(2015) The Nodal signaling pathway controls left–right 
asymmetric development in amphioxus. Evodevo 6:5. 
doi:10.1186/2041-9139-6-5
Strizzi L, Sandomenico A, Margaryan NV, Focà A, Sanguigno L, 
Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, 
Seftor RE, Khalkhali-Ellis Z, Leonardi A, Ruvo M, Hendrix 
MJ (2015) Effects of a novel Nodal-targeting monoclonal anti-
body in melanoma. Oncotarget 6:34071–34086. doi:10.18632/
oncotarget.6049
Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich 
phosphoprotein that binds to the SH3 domain of the Yes proto-
oncogene product. Oncogene 9:2145–2152
Grannas K, Arngården L, Lönn P, Mazurkiewicz M, Blokzijl A, Zieba 
A, Söderberg O (2015) Crosstalk between Hippo and TGFβ: 
Subcellular Localization of YAP/TAZ/Smad Complexes. J Mol 
Biol 427(21):3407–3415
Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, 
Wheaton WW, Nickoloff BJ, Topczewski J, Hendrix MJ (2006) 
Embryonic and tumorigenic pathways converge via Nodal sign-
aling: role in melanoma aggressiveness. Nat Med 12(8):925–932
Zhang H, von Gise A, Liu Q, Hu T, Tian X, He L, Pu W, Huang X, He 
L, Cai CL, Camargo FD, Pu WT, Zhou B (2014) Yap1 is required 
for endothelial to mesenchymal transition of the atrioventricular 
cushion. J Biol Chem 289(27):18681–18692
Vandeputte C, Docherty JR (2002) Vascular actions of 3,4-methylen-
edioxymethamphetamine in alpha(2A/D)-adrenoceptor knockout 
mice. Eur J Pharmacol 457(1):45–49
